Chlamydial Protease-Like Activity Factor Induces Protective Immunity against Genital Chlamydial Infection in Transgenic Mice That Express the Human HLA-DR4 Allele
- 1 December 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (12) , 6722-6729
- https://doi.org/10.1128/iai.01119-06
Abstract
There is no licensed vaccine available against Chlamydia trachomatis , the leading cause of bacterial sexually transmitted disease. We have found that intranasal immunization with recombinant chlamydial protease-like activity factor (CPAF) induces CD4 + T-cell- and gamma interferon (IFN-γ)-dependent protective immunity against murine genital chlamydial infection, thus making CPAF a viable vaccine candidate for further characterization. HLA-DR4 is the predominant allele involved in chlamydial antigen presentation to CD4 + T cells in humans. We used engineered mice that lack endogenous major histocompatibility complex class II (MHC-II) alleles but express a human HLA allele (HLA-DR4 transgenic [tg] mice) to examine primary immune and CPAF-mediated responses against genital Chlamydia muridarum challenge. Upon primary bacterial exposure, HLA-DR4 tg mice developed Chlamydia -specific IFN-γ and antibody production and resolved the infection within 30 days, similar to challenged conventional C57BL/6 animals. Moreover, C. muridarum -challenged HLA-DR4 tg mice exhibited CPAF-specific antibody and IFN-γ production. Upon CPAF-plus-interleukin-12 (IL-12) vaccination, HLA-DR4 tg animals exhibited robust CPAF-specific IFN-γ production and elevated titers of anti-CPAF total antibody and immunoglobulin G2a (IgG2a) and lower titers of IgG2b and IgG1 antibodies. HLA-DR4 tg and C57BL/6 mice vaccinated with CPAF plus IL-12 resolved the primary genital chlamydial infection significantly earlier than mock-immunized animals, whereas similarly vaccinated MHC class II-deficient mice displayed minimal antigen-specific immune responses and failed to resolve the infection even at 30 days postchallenge. Together, these results demonstrate the importance of human HLA-DR4 molecules in the recognition and presentation of CPAF epitopes, leading to the generation of protective antichlamydial immunity and making these mice a valuable model for mapping HLA-DR4-restricted chlamydial epitopes.Keywords
This publication has 28 references indexed in Scilit:
- Inhibition of Proteolytic Activity of a Chlamydial Proteasome/Protease-Like Activity Factor by Antibodies from Humans Infected with Chlamydia trachomatisInfection and Immunity, 2005
- Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain)Journal of Human Hypertension, 2005
- Human Antibody Responses to a Chlamydia-Secreted Protease FactorInfection and Immunity, 2004
- Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient miceCellular Immunology, 2004
- Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity againstStreptococcus pneumoniaeInfectionInfection and Immunity, 2001
- Identification of a Chlamydial Protease–Like Activity Factor Responsible for the Degradation of Host Transcription FactorsThe Journal of Experimental Medicine, 2001
- HLA GENE AND HAPLOTYPE FREQUENCIES IN THE NORTH AMERICAN POPULATIONTransplantation, 1997
- Pelvic Inflammatory Disease and FertilitySexually Transmitted Diseases, 1992
- Conjunctival epithelial cells infected with Chlamydia trachomatis express HLA-DR antigens.British Journal of Ophthalmology, 1989
- Antigen‐Specific Proliferative Human T‐Lymphocyte Clones with Specificity for Chlamydia trachomatisScandinavian Journal of Immunology, 1983